• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sunovion Pharmaceuticals Europe Ltd. (Sunovion Europe) - Articles and news items

vienna

New post-hoc analyses extend understanding of the efficacy and safety of lurasidone in the treatment of schizophrenia

Industry news / 31 March 2015 / Victoria White

Takeda and Sunovion today announced the results from 3 post-hoc analyses evaluating the efficacy and safety of lurasidone in patients with schizophrenia…

Takeda Logo

Multiple scientific posters supporting the efficacy, safety and tolerability of once-daily Latuda® (lurasidone) are presented at the 27th ECNP Congress

Industry news / 22 October 2014 / Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc

Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. presented new evidence supporting the use of Latuda® (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, during multiple poster sessions at the 27th European College of Neuropsychopharmacology…

Sunovion Europe Logo

Sunovion Europe announces new name

Industry news, News / 2 April 2013 / Munro & Forster

Sunovion Europe has formally changed its name from Dainippon Sumitomo Pharma Europe Ltd. (DSPE)…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +